All In Biotech

Drug Trial Radar · NCT02607449

FS-1 Drug for Treatment of Multiple Drug-resistant Tuberculosis

Randomized, Placebo-controlled Study of Safety and Therapeutic Efficacy of the Drug FS-1 in the Oral Dosage Form in Drug-resistant Pulmonary Tuberculosis

Last checked: Nov 19, 2026Latest source record: May 24, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 344 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

344

Actual

Start

Dec 2013

Primary completion

Aug 2020

Study completion Oct 2020

Sponsor

Sponsor type
Industry
Collaborators
Phthisiopulmonology Center of Almaty, Kazakhstan; National Scientific Center of Phthisiopulmonology, Kazakhstan; Karaganda Medical University; West Kazakhstan Marat Ospanov Medical University; Semey State Medical University; National Center of Phthisiatry, Bishkek, Kyrgyzstan; Invivo laboratory, Kazakhstan
First posted
Nov 18, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Drug-resistant tuberculosis is becoming a major problem for the whole humanity, and development of new Anti-TB drugs is of great importance. Since Kazakhstan is a country with the high burden of tuberculosis, the Government of the Republic of Kazakhstan has founded initiative on the development of new Anti-TB drug to treat drug-resistant forms of this infectious disease. JSC "Scientific Center for Anti-infectious Drugs" has developed original drug FS-1 for the treatment of multidrug resistant tuberculosis (MDR-TB).

Conditions

  • Tuberculosis, MDR

Interventions

  • FS-1Drug

    FS-1 is a liquid solution for internal intake and has antimicrobial and antibacterial activities.

  • PlaceboDrug

    Placebo without any active pharmaceutical ingredients

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to persistently negative sputum culturesTime frame: 18 months
  2. Proportion of Patients with persistently negative sputum cultures (SCC)Time frame: 12 months

Locations

6 sites in 2 countries. Site status is shown where the registry gives one.

  • National scientific center of phthisiopulmonology Ministry of health of the Republic of Kazakhstan

    Almaty, Kazakhstan

  • Center of Phthisiopulmonology of the Public Health Administration of Almaty

    Almaty, Kazakhstan

  • Karaganda Medical University

    Karaganda, Kazakhstan

  • Semey Medical University

    Semey, East Kazakhstan, Kazakhstan

  • West Kazakhstan Marat Ospanov Medical University

    Aktobe, West Kazakhstan, Kazakhstan

  • National Center of Phthisiatry

    Bishkek, Kyrgyzstan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.